Los Angeles Capital Management LLC Cuts Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Los Angeles Capital Management LLC lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 43.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,360 shares of the company’s stock after selling 70,967 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Medpace were worth $31,017,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. State Street Corp grew its position in shares of Medpace by 7.2% during the third quarter. State Street Corp now owns 752,957 shares of the company’s stock worth $251,337,000 after purchasing an additional 50,312 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Medpace by 7.6% during the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock worth $209,885,000 after purchasing an additional 44,371 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after purchasing an additional 109,886 shares in the last quarter. American Capital Management Inc. grew its position in shares of Medpace by 2.6% during the third quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock worth $127,060,000 after purchasing an additional 9,592 shares in the last quarter. Finally, FMR LLC grew its position in shares of Medpace by 11.8% during the third quarter. FMR LLC now owns 231,019 shares of the company’s stock worth $77,114,000 after purchasing an additional 24,362 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Robert W. Baird increased their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $381.44.

Medpace Trading Down 1.0 %

Shares of Medpace stock opened at $340.92 on Wednesday. The stock has a 50 day moving average of $342.87 and a 200 day moving average of $346.24. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The firm has a market cap of $10.39 billion, a PE ratio of 26.99, a PEG ratio of 3.81 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.